Sign up
Pharma Capital

Concepta ‘delighted’ as number of myLotus pregnancies moves into double figures

myLotus was only launched in the UK at the end of 2018, but it has already helped more than ten women conceive
myLotus helps women figure out their most fertile days, boosting their chances of getting pregnant

The number of women who have become pregnant after using Concepta PLC’s (LON:CPT) myLotus fertility test is now in double figures, with the first births expected later this year.

“We are extremely proud and delighted to announce the growing number of pregnancies and look forward to our first myLotus 'live births' later this year,” said chairman Matthew Walls.

“Whilst our marketing and brand profile are nascent our early pregnancy statistics are impressive. Following the recent myLotus launch our first wave of users are women who have struggled to conceive naturally, some after trying for many years.”

He added: “These women and their testimonials are now providing real world evidence of the value of the myLotus technology as a breakthrough in helping women increase their chances of a natural pregnancy.”

WATCH: Concepta chairman sees significant opportunity for its myLotus fertility test

myLotus is an easy-to-use home test that has been developed for women who have been trying to conceive without any luck for at least six months.

It measures hormone levels in urine to identify the woman’s most fertile days and can also help to explain the apparent lack of fertility.

A smartphone app helps users keep track of their results, which can then be shared with doctors to help improve the chances of conception.

The test was launched in the UK at the end of 2018, and a recent tie-up with Boots means it can now be found in the chemist’s stores up and down the country.

Concepta expects to sign more business-to-business deals “over the coming months”, it said today.

In lunchtime trading, shares in Concepta were 4.3% higher at  2.45p.

 -- Adds share price -- 

View full CPT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.